Literature DB >> 22796100

Assessing illicit drug use among adults with schizophrenia.

Richard A Van Dorn1, Sarah L Desmarais, M Scott Young, Brian G Sellers, Marvin S Swartz.   

Abstract

Accurate drug use assessment is vital to understanding the prevalence, course, treatment needs, and outcomes among individuals with schizophrenia because they are thought to remain at long-term risk for negative drug use outcomes, even in the absence of drug use disorder. This study evaluated self-report and biological measures for assessing illicit drug use in the Clinical Antipsychotic Trials of Intervention Effectiveness study (N=1460). Performance was good across assessment methods, but differed as a function of drug type, measure, and race. With the Structured Clinical Interview for DSM-III-R as the criterion, self-report evidenced greater concordance, accuracy and agreement overall, and for marijuana, cocaine, and stimulants specifically, than did urinalysis and hair assays, whereas biological measures outperformed self-report for detection of opiates. Performance of the biological measures was better when self-report was the criterion, but poorer for black compared white participants. Overall, findings suggest that self-report is able to garner accurate information regarding illicit drug use among adults with schizophrenia. Further work is needed to understand the differential performance of assessment approaches by drug type, overall and as a function of race, in this population.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22796100      PMCID: PMC3474887          DOI: 10.1016/j.psychres.2012.05.028

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  50 in total

1.  Hair analysis for drugs of abuse. Hair color and race differentials or systematic differences in drug preferences?

Authors:  R C Kelly; T Mieczkowski; S A Sweeney; J A Bourland
Journal:  Forensic Sci Int       Date:  2000-01-10       Impact factor: 2.395

2.  Pharmacological criteria that can affect the detection of doping agents in hair.

Authors:  P Kintz; V Cirimele; B Ludes
Journal:  Forensic Sci Int       Date:  2000-01-10       Impact factor: 2.395

Review 3.  Evidence for bias in hair testing and procedures to correct bias.

Authors:  D A Kidwell; E H Lee; S F DeLauder
Journal:  Forensic Sci Int       Date:  2000-01-10       Impact factor: 2.395

Review 4.  A review of biological indicators of illicit drug use, practical considerations and clinical usefulness.

Authors:  K Wolff; M Farrell; J Marsden; M G Monteiro; R Ali; S Welch; J Strang
Journal:  Addiction       Date:  1999-09       Impact factor: 6.526

Review 5.  Managing comorbid schizophrenia and substance abuse.

Authors:  R E Drake; K T Mueser
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

Review 6.  Clinically useful assessments: substance use and comorbid psychiatric disorders.

Authors:  K B Carey
Journal:  Behav Res Ther       Date:  2002-11

Review 7.  Statistical examination of hair color as a potential biasing factor in hair analysis.

Authors:  T Mieczkowski; R Newel
Journal:  Forensic Sci Int       Date:  2000-01-10       Impact factor: 2.395

8.  Hair testing and self-report of cocaine use.

Authors:  Claudia Vignali; Cristiana Stramesi; Micol Vecchio; Angelo Groppi
Journal:  Forensic Sci Int       Date:  2011-06-08       Impact factor: 2.395

9.  Cocaine, benzoylecgonine, amphetamine, and N-acetylamphetamine binding to melanin subtypes.

Authors:  Chad R Borges; Jeanette C Roberts; Diana G Wilkins; Douglas E Rollins
Journal:  J Anal Toxicol       Date:  2003-04       Impact factor: 3.367

10.  Detection of illicit substance use among persons with schizophrenia by radioimmunoassay of hair.

Authors:  Marvin S Swartz; Jeffrey W Swanson; Michael J Hannon
Journal:  Psychiatr Serv       Date:  2003-06       Impact factor: 3.084

View more
  10 in total

1.  Heavy cannabis use prior psychosis in schizophrenia: clinical, cognitive and neurological evidences for a new endophenotype?

Authors:  Jasmina Mallet; Nicolas Ramoz; Yann Le Strat; Philip Gorwood; Caroline Dubertret
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-02-11       Impact factor: 5.270

2.  Evidence for differential opioid use disorder in schizophrenia in an addiction treatment population.

Authors:  Joshua Chiappelli; Shuo Chen; Ann Hackman; L Elliot Hong
Journal:  Schizophr Res       Date:  2017-05-06       Impact factor: 4.939

3.  Accuracy of self-report, biological tests, collateral reports and clinician ratings in identifying substance use disorders among adults with schizophrenia.

Authors:  Sarah L Desmarais; Richard A Van Dorn; Brian G Sellers; M Scott Young; Marvin S Swartz
Journal:  Psychol Addict Behav       Date:  2012-12-31

4.  Latent class analysis of discordance between results of drug use assessments in the CATIE data.

Authors:  Kiersten L Johnson; Sarah L Desmarais; Marvin S Swartz; Richard A Van Dorn
Journal:  Schizophr Res       Date:  2014-12-01       Impact factor: 4.939

5.  Psychosis and Comorbid Opioid Use Disorder: Characteristics and Outcomes in Opioid Substitution Therapy.

Authors:  Rachel Lamont; Tea Rosic; Nitika Sanger; Zainab Samaan
Journal:  Schizophr Bull Open       Date:  2020-03-02

6.  Drug and alcohol trajectories among adults with schizophrenia: data from the CATIE study.

Authors:  Richard A Van Dorn; Sarah L Desmarais; Stephen J Tueller; Jennifer M Jolley; Kiersten L Johnson; Marvin S Swartz
Journal:  Schizophr Res       Date:  2013-05-29       Impact factor: 4.939

7.  Letter to the editor: Critique of Bahorik et al. (2013)--'Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors'.

Authors:  Richard A Van Dorn; Sarah L Desmarais; Marvin S Swartz; M Scott Young; Brian G Sellers
Journal:  Psychol Med       Date:  2013-10-28       Impact factor: 7.723

8.  Screening for substance use disorders in first-episode psychosis: implications for readmission.

Authors:  Albert Batalla; Clemente Garcia-Rizo; Pere Castellví; Emili Fernandez-Egea; Murat Yücel; Eduard Parellada; Brian Kirkpatrick; Rocío Martin-Santos; Miguel Bernardo
Journal:  Schizophr Res       Date:  2013-03-19       Impact factor: 4.939

9.  Psycho-education for substance use and antisocial personality disorder: a randomized trial.

Authors:  Birgitte Thylstrup; Sidsel Schrøder; Morten Hesse
Journal:  BMC Psychiatry       Date:  2015-11-14       Impact factor: 3.630

10.  Jail-to-community treatment continuum for adults with co-occurring substance use and mental disorders: study protocol for a pilot randomized controlled trial.

Authors:  Richard A Van Dorn; Sarah L Desmarais; Candalyn B Rade; Elizabeth N Burris; Gary S Cuddeback; Kiersten L Johnson; Stephen J Tueller; Megan L Comfort; Kim T Mueser
Journal:  Trials       Date:  2017-08-04       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.